---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-063481"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2026-06-01T20:01:27+00:00"
generated_at: "2026-06-01T20:04:53.115064+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

## Summary
- Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
- Cannot dose ORKA-001 in combination IBD trial before June 1, 2028, or monotherapy before June 1, 2030.
- If material transaction occurs (e.g., change of control), monotherapy restriction ends June 1, 2028.
- Paragon's exclusivity for monospecific antibodies in IBD extended to October 11, 2029.

## SEC filing metadata
- accession: 0001213900-26-063481
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2026-06-01T20:01:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/0001213900-26-063481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390026063481/ea0292876-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-063481
- JSON: https://secwatch.observer/filing/0001213900-26-063481.json
- Plain text: https://secwatch.observer/filing/0001213900-26-063481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.